Bottlenecks and opportunities in immunotherapy for glioma: a narrative review
Glioma is the most aggressive brain tumor having invasive ability and a highly heterogeneous phenotype. Many patients with glioma respond poorly to traditional surgery or temozolomide-based chemotherapy. Over the past few decades, developments in immunotherapeutic strategies have provided newer insi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2022-12-01
|
| Series: | Journal of Bio-X Research |
| Online Access: | http://journals.lww.com/10.1097/JBR.0000000000000135 |
| _version_ | 1797947099936980992 |
|---|---|
| author | Ying Shi Mengwan Wu Yuyang Liu Ling Chen Xiuwu Bian Chuan Xu |
| author_facet | Ying Shi Mengwan Wu Yuyang Liu Ling Chen Xiuwu Bian Chuan Xu |
| author_sort | Ying Shi |
| collection | DOAJ |
| description | Glioma is the most aggressive brain tumor having invasive ability and a highly heterogeneous phenotype. Many patients with glioma respond poorly to traditional surgery or temozolomide-based chemotherapy. Over the past few decades, developments in immunotherapeutic strategies have provided newer insights into the treatment of gliomas. Immunotherapy is based on the principle of normalization or recovery of T cell-mediated anti-tumor immunoreaction. Different innovative strategies have been used; these include enhancement of immunogenicity by administration of tumor antigens or dendritic cell vaccines, replenishment of cytotoxic T cells by adoptive T cell transfer, repair of exhausted T cells by immune checkpoint inhibitors, and the use of other immune activators such as oncolytic viruses. However, many immunotherapy-based clinical trials did not meet the expected therapeutic endpoints in patients with glioma. Gliomas use unique strategies to generate an immune-suppressive microenvironment; these include limiting immunogenicity and repressing T cell infiltration or activation. This may be addressed by the incorporation of immunotherapy with standard therapy or by use of certain innovative approaches such as tumor-treating fields. In this review, we summarize the updated immunotherapies in glioma and discuss current limitations and future prospects. |
| first_indexed | 2024-04-10T21:21:24Z |
| format | Article |
| id | doaj.art-13cf2984fe4349b292abe268b3b2a269 |
| institution | Directory Open Access Journal |
| issn | 2096-5672 |
| language | English |
| last_indexed | 2024-04-10T21:21:24Z |
| publishDate | 2022-12-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Journal of Bio-X Research |
| spelling | doaj.art-13cf2984fe4349b292abe268b3b2a2692023-01-20T02:41:34ZengWolters Kluwer HealthJournal of Bio-X Research2096-56722022-12-015415116210.1097/JBR.0000000000000135202212000-00003Bottlenecks and opportunities in immunotherapy for glioma: a narrative reviewYing Shi0Mengwan Wu1Yuyang Liu2Ling Chen3Xiuwu Bian4Chuan Xu5a Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Provincea Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan Provinceb Department of Neurosurgery, Chinese People’s Liberation Army (PLA) General Hospital, Beijingb Department of Neurosurgery, Chinese People’s Liberation Army (PLA) General Hospital, Beijingc Institute of Pathology & Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqinga Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan ProvinceGlioma is the most aggressive brain tumor having invasive ability and a highly heterogeneous phenotype. Many patients with glioma respond poorly to traditional surgery or temozolomide-based chemotherapy. Over the past few decades, developments in immunotherapeutic strategies have provided newer insights into the treatment of gliomas. Immunotherapy is based on the principle of normalization or recovery of T cell-mediated anti-tumor immunoreaction. Different innovative strategies have been used; these include enhancement of immunogenicity by administration of tumor antigens or dendritic cell vaccines, replenishment of cytotoxic T cells by adoptive T cell transfer, repair of exhausted T cells by immune checkpoint inhibitors, and the use of other immune activators such as oncolytic viruses. However, many immunotherapy-based clinical trials did not meet the expected therapeutic endpoints in patients with glioma. Gliomas use unique strategies to generate an immune-suppressive microenvironment; these include limiting immunogenicity and repressing T cell infiltration or activation. This may be addressed by the incorporation of immunotherapy with standard therapy or by use of certain innovative approaches such as tumor-treating fields. In this review, we summarize the updated immunotherapies in glioma and discuss current limitations and future prospects.http://journals.lww.com/10.1097/JBR.0000000000000135 |
| spellingShingle | Ying Shi Mengwan Wu Yuyang Liu Ling Chen Xiuwu Bian Chuan Xu Bottlenecks and opportunities in immunotherapy for glioma: a narrative review Journal of Bio-X Research |
| title | Bottlenecks and opportunities in immunotherapy for glioma: a narrative review |
| title_full | Bottlenecks and opportunities in immunotherapy for glioma: a narrative review |
| title_fullStr | Bottlenecks and opportunities in immunotherapy for glioma: a narrative review |
| title_full_unstemmed | Bottlenecks and opportunities in immunotherapy for glioma: a narrative review |
| title_short | Bottlenecks and opportunities in immunotherapy for glioma: a narrative review |
| title_sort | bottlenecks and opportunities in immunotherapy for glioma a narrative review |
| url | http://journals.lww.com/10.1097/JBR.0000000000000135 |
| work_keys_str_mv | AT yingshi bottlenecksandopportunitiesinimmunotherapyforgliomaanarrativereview AT mengwanwu bottlenecksandopportunitiesinimmunotherapyforgliomaanarrativereview AT yuyangliu bottlenecksandopportunitiesinimmunotherapyforgliomaanarrativereview AT lingchen bottlenecksandopportunitiesinimmunotherapyforgliomaanarrativereview AT xiuwubian bottlenecksandopportunitiesinimmunotherapyforgliomaanarrativereview AT chuanxu bottlenecksandopportunitiesinimmunotherapyforgliomaanarrativereview |